Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
12 articles
Newest firstHintergrundBis vor 25 Jahren waren zyklische Brechattacken unter chronischem Cannabiseinfluss nahezu unbekannt. Nach der Legalisierung nichtmedizinischen Cannabis in Nordamerika und der damit einhergehenden Zunahme des Cannabiskonsums, einschließlich hochpotenter Sorten steigt dort die Zahl der Patienten mit cannabisbezogenem zyklischem Erbrechen. Die ROME-IV-Kriterien der Rome Foundation definieren das cannabisin…
Open article record in new tab ↗Cannabinoid hyperemesis syndrome (CHS) is an emerging disorder in chronic cannabis users, characterized by recurrent nausea, vomiting, severe abdominal pain, and compulsive hot bathing. We report a case of CHS complicated by profound lactic acidosis (lactate 6.1 mmol/L), highlighting this metabolic derangement as a secondary effect of severe dehydration and physiological stress from intractable vomiting and pain.…
Open article record in new tab ↗Cannabinoid hyperemesis syndrome (CHS) is a serious condition primarily seen in chronic cannabis users, characterized by persistent cycles of severe nausea and vomiting, often leading to frequent emergency room visits. Accurate diagnosis is crucial due to the overlap with other gastrointestinal disorders. The traditional use of antiemetics such as ondansetron often fails to alleviate symptoms, making CHS difficult…
Open article record in new tab ↗Background/Objectives: Cannabinoid Hyperemesis Syndrome (CHS), associated with long-term cannabinoid use, has been increasingly observed in emergency room visits as more states in the U.S. have legislatively permitted medical and recreational marijuana use. The acute management of CHS primarily focuses on antiemetic treatment and supportive care. However, both the condition itself and the antiemetic drugs, such as…
Open article record in new tab ↗BackgroundHospitalization is often necessary for individuals with Bipolar affective Disorder (BAD) during severe manic or depressive episodes, as well as for stabilizing treatment regimens. However, a significant proportion of patients admitted for treatment of BAD abscond or leave the hospital without permission during their stay. In addition, patients managed for BAD may have unique characteristics that might fo…
Open article record in new tab ↗Objectives The duration of administration (e.g., subchronic or chronic) of haloperidol may influence its adverse effects. We studied the effects of duration of administration of haloperidol on body weight and fasting blood sugar (FBS). In addition, we examined whether orally administered cannabidiol (CBD) had any putative mitigating influence on haloperidol-induced body weight changes and FBS elevation. Methods Ha…
Open article record in new tab ↗Cannabidiol, a compound of Cannabis sativa, has been proposed as an alternative treatment of schizophrenia. Preclinical and clinical data have suggested that cannabidiol shares more similarity with atypical antipsychotics than typical, both of which are customarily used to manage schizophrenia symptoms. While oligodendrocytes are known to be relevant targets of antipsychotics, the biochemical knowledge in this reg…
[This corrects the article DOI: 10.3389/fnmol.2021.673144.].
Open article record in new tab ↗Introduction Intravenous haloperidol has been shown to decrease milligram morphine equivalents (MME) of analgesia and reduce hospital admissions for diabetic gastroparesis. The objective of this study was to evaluate whether haloperidol decreases MME for the treatment of non-specific abdominal pain diagnoses in the emergency department (ED), including gastroparesis, cyclic vomiting, cannabinoid hyperemesis syndrom…
Open article record in new tab ↗Cortical circuit dysfunction is thought to be an underlying mechanism of schizophrenia (SZ) pathophysiology with normalization of aberrant circuit activity proposed as a biomarker for antipsychotic efficacy. Cannabidiol (CBD) shows potential as an adjunctive antipsychotic therapy; however, potential sex effects in these drug interactions remain unknown. In the present study, we sought to elucidate sex effects of C…
A high percentage of persons with Schizophrenia also uses Cannabis and this may potentially alter the therapeutic benefits of the antipsychotic medications prescribed. The aim of this study was to assess the impact of Cannabis usage on antipsychotic therapy of sleep disturbances in schizophrenia subjects. Male subjects, ≥18 years, admitted to the University Hospital of the West Indies psychiatric ward between Octo…
Open article record in new tab ↗Rewarding effects have been related to enhanced dopamine (DA) release in corticolimbic and basal ganglia structures. The DAergic and endocannabinoid interaction in the responses to reward is described. This study investigated the link between endocannabinoid and DAergic transmission in the processes that are related to response to two types of reward, palatable food and novelty. Mice treated with drugs acting on e…
Open article record in new tab ↗